Contact
searchSearch
HMP Global

February 2014 - FRMC

Cost Savings with Bortezomib, Cyclophosphamide, and Dexamethasone
02/19/2014
Tim Casey
New Orleans—Patients with untreated multiple myeloma had a cost savings of approximately $29,000 per treatment course if they received bortezomib, cyclophosphamide, and dexamethasone (BCD) compared with a group taking bortezomib,...
New Orleans—Patients with untreated multiple myeloma had a cost savings of approximately $29,000 per treatment course if they received bortezomib, cyclophosphamide, and dexamethasone (BCD) compared with a group taking bortezomib,...
New Orleans—Patients with...
02/19/2014
First Report Managed Care
Omacetaxine for CML
02/19/2014
Tim Casey
New Orleans—After at least 24 months of follow-up, heavily pretreated patients with chronic phase or accelerated phase chronic myeloid leukemia (CML) had clinically meaningful and durable responses to omacetaxine, according to a subset...
New Orleans—After at least 24 months of follow-up, heavily pretreated patients with chronic phase or accelerated phase chronic myeloid leukemia (CML) had clinically meaningful and durable responses to omacetaxine, according to a subset...
New Orleans—After at least 24...
02/19/2014
First Report Managed Care
Dabigatran to Treat Patients with Acute Venous Thromboembolism
02/19/2014
Tim Casey
New Orleans—A prespecified subgroup analysis of 2 randomized, phase 3 trials that included patients with acute venous thromboembolism (VTE) found that there was no difference in recurrent VTE or VTE-related mortality if they received...
New Orleans—A prespecified subgroup analysis of 2 randomized, phase 3 trials that included patients with acute venous thromboembolism (VTE) found that there was no difference in recurrent VTE or VTE-related mortality if they received...
New Orleans—A prespecified...
02/19/2014
First Report Managed Care
Treatment with Rituximab in Clinics and Offices versus Hospitals
02/19/2014
Tim Casey
New Orleans—A retrospective analysis of a managed care claims database found that from 2007 to 2012, there was an increase in the proportion of patients who took rituximab to treat diffuse large B-cell lymphoma (DLBCL) in a hospital setting...
New Orleans—A retrospective analysis of a managed care claims database found that from 2007 to 2012, there was an increase in the proportion of patients who took rituximab to treat diffuse large B-cell lymphoma (DLBCL) in a hospital setting...
New Orleans—A retrospective...
02/19/2014
First Report Managed Care
Phase 2 Trial of Obinutuzumab for Advanced DLBCL
02/19/2014
Tim Casey
New Orleans—Patients newly diagnosed with diffuse large B-cell lymphoma (DLBCL) tolerated a regimen of obinutuzumab and chemotherapy, according to a phase 2, open label, multicenter, single arm trial. The authors mentioned preliminary results...
New Orleans—Patients newly diagnosed with diffuse large B-cell lymphoma (DLBCL) tolerated a regimen of obinutuzumab and chemotherapy, according to a phase 2, open label, multicenter, single arm trial. The authors mentioned preliminary results...
New Orleans—Patients newly...
02/19/2014
First Report Managed Care
Allogeneic HSCT and Cognitive Impairment
02/19/2014
Tim Casey
Patients undergoing allogeneic hematopoietic stem cell transplantation had cognitive impairment on executive function, processing speed, and verbal fluency.
Patients undergoing allogeneic hematopoietic stem cell transplantation had cognitive impairment on executive function, processing speed, and verbal fluency.
Patients undergoing allogeneic...
02/19/2014
First Report Managed Care
Economic Benefit Suggested with Abatacept for RA
02/19/2014
Mary Beth Nierengarten
  San Diego—Use of abatacept as first- or second-line treatment for patients with moderate-to-severe rheumatoid arthritis (RA) may have an economic benefit over other biologic disease-modifying antirheumatic drugs (DMARDs) agents, as...
  San Diego—Use of abatacept as first- or second-line treatment for patients with moderate-to-severe rheumatoid arthritis (RA) may have an economic benefit over other biologic disease-modifying antirheumatic drugs (DMARDs) agents, as...
  San Diego—Use of abatacept as...
02/19/2014
First Report Managed Care
Conference Insider
Ustekinumab for Patients with Active PsA Long-Term
02/19/2014
Mary Beth Nierengarten
San Diego—The efficacy and safety of ustekinumab as treatment for active psoriatic arthritis (PsA) is maintained at 100 weeks follow-up, according to long-term data presented at the ACR/ARHP meeting.
San Diego—The efficacy and safety of ustekinumab as treatment for active psoriatic arthritis (PsA) is maintained at 100 weeks follow-up, according to long-term data presented at the ACR/ARHP meeting.
San Diego—The efficacy and...
02/19/2014
First Report Managed Care
Efficacy of Golimumab for Refractory RA Maintained Over 5 Years
02/19/2014
Mary Beth Nierengarten
San Diego—Long-term outcomes show that golimumab maintains its efficacy for patients with active rheumatoid arthritis (RA) who failed prior biologic therapy with anti-tumor necrosis factor (TNF) therapy.
San Diego—Long-term outcomes show that golimumab maintains its efficacy for patients with active rheumatoid arthritis (RA) who failed prior biologic therapy with anti-tumor necrosis factor (TNF) therapy.
San Diego—Long-term outcomes...
02/19/2014
First Report Managed Care
Tofacitinib Monotherapy Offers Significant Benefits for Active RA
02/19/2014
Mary Beth Nierengarten
San Diego—In patients with rheumatoid arthritis (RA), tofacitinib monotherapy significantly inhibits progression of structural damage, improves signs and symptoms of disease, and improves function over 2 years compared to patients treated...
San Diego—In patients with rheumatoid arthritis (RA), tofacitinib monotherapy significantly inhibits progression of structural damage, improves signs and symptoms of disease, and improves function over 2 years compared to patients treated...
San Diego—In patients with...
02/19/2014
First Report Managed Care
Evaluating the Safety and Efficacy of Rituxmab for IgG4-Related Disease
02/19/2014
Mary Beth Nierengarten
San Diego—Preliminary results of a prospective, open-label, pilot trial showed that rituximab may be a safe and effective treatment option for patients with immunoglobulin G4-related disease (IgG4-RD), a multi-organ, fibro-inflammatory...
San Diego—Preliminary results of a prospective, open-label, pilot trial showed that rituximab may be a safe and effective treatment option for patients with immunoglobulin G4-related disease (IgG4-RD), a multi-organ, fibro-inflammatory...
San Diego—Preliminary results of...
02/19/2014
First Report Managed Care
Benefit of Urate-Lowering Therapy on Progression of Renal Disease
02/19/2014
Mary Beth Nierengarten
San Diego—For patients with hyperuricemia, urate-lowering therapy alone may not directly reduce the risk of kidney disease but may reduce other outcomes related to renal disease progression particularly in patients who achieve a serum acid of...
San Diego—For patients with hyperuricemia, urate-lowering therapy alone may not directly reduce the risk of kidney disease but may reduce other outcomes related to renal disease progression particularly in patients who achieve a serum acid of...
San Diego—For patients with...
02/19/2014
First Report Managed Care
Biologics More Expensive than Triple Therapy for Early Aggressive RA
02/19/2014
Mary Beth Nierengarten
San Diego—For patients with early aggressive rheumatoid arthritis (RA), initial treatment with triple disease-modifying anti-rheumatic drug (DMARD) therapy is more cost-effective long-term than initial treatment with either an immediate or...
San Diego—For patients with early aggressive rheumatoid arthritis (RA), initial treatment with triple disease-modifying anti-rheumatic drug (DMARD) therapy is more cost-effective long-term than initial treatment with either an immediate or...
San Diego—For patients with...
02/19/2014
First Report Managed Care
tREACH Study Results for Early RA Treatments
02/19/2014
Mary Beth Nierengarten
San Diego—In patients with early rheumatoid arthritis (RA), treatment with triple disease-modifying antirheumatic drug (DMARD) therapy was found superior to methotrexate monotherapy, even after 12 months of therapy. The superior benefit of...
San Diego—In patients with early rheumatoid arthritis (RA), treatment with triple disease-modifying antirheumatic drug (DMARD) therapy was found superior to methotrexate monotherapy, even after 12 months of therapy. The superior benefit of...
San Diego—In patients with early...
02/19/2014
First Report Managed Care
Pregabalin for Patients with Fibromyalgia Also on Antidepressants
02/19/2014
Mary Beth Nierengarten
San Diego—In patients with fibromyalgia on antidepressants for comorbid depression, treatment with pregabalin safely and effectively reduces pain severity, according to the first study to examine this combination of medications for...
San Diego—In patients with fibromyalgia on antidepressants for comorbid depression, treatment with pregabalin safely and effectively reduces pain severity, according to the first study to examine this combination of medications for...
San Diego—In patients with...
02/19/2014
First Report Managed Care
Adverse Event Rates among Medicare Patients with Common Medical Conditions
02/19/2014
Sarah O'Brien
A study of the adverse event rates among Medicare patients with common medical conditions discovered a decline in patients hospitalized for acute myocardial infarction (MI) or congestive heart failure (CHF), while no change was seen for...
A study of the adverse event rates among Medicare patients with common medical conditions discovered a decline in patients hospitalized for acute myocardial infarction (MI) or congestive heart failure (CHF), while no change was seen for...
A study of the adverse event...
02/19/2014
First Report Managed Care
Health Coverage for Hypertension Management
02/19/2014
Kerri Fitzgerald
With the introduction of the Patient Protection and Affordable Care Act (ACA), the debate on universal healthcare has become heated. Cross-country analysis can examine health system structures and outcomes, providing information on how...
With the introduction of the Patient Protection and Affordable Care Act (ACA), the debate on universal healthcare has become heated. Cross-country analysis can examine health system structures and outcomes, providing information on how...
With the introduction of the...
02/19/2014
First Report Managed Care
CAC Volume Positively Associated with CHD and CVD Risk
02/19/2014
Sarah O'Brien
A recent study sought to determine the independent associations of coronary artery calcium (CAC) volume and CAC density with incident cardiovascular disease (CVD), including coronary heart disease (CHD) [JAMA. 2014;311(3):271-278]. CAC...
A recent study sought to determine the independent associations of coronary artery calcium (CAC) volume and CAC density with incident cardiovascular disease (CVD), including coronary heart disease (CHD) [JAMA. 2014;311(3):271-278]. CAC...
A recent study sought to...
02/19/2014
First Report Managed Care
Radiation Exposure from Cardiac Imaging Underestimated
02/19/2014
Mary Mihalovic
Many physicians greatly underestimate the amount of radiation patients are exposed to during the most commonly administered tests, according to a recent literature review [Eur Heart J. DOI:10.1093/eurheartj/eht394]. Increased awareness and...
Many physicians greatly underestimate the amount of radiation patients are exposed to during the most commonly administered tests, according to a recent literature review [Eur Heart J. DOI:10.1093/eurheartj/eht394]. Increased awareness and...
Many physicians greatly...
02/19/2014
First Report Managed Care
Adhesive Patch Detects More Arrhythmias Than Conventional Monitoring
02/19/2014
Mary Mihalovic
An adhesive electrocardiographic (ECG) monitoring patch detected significantly more arrhythmias compared with the conventionally used Holter monitor, according to results from a recent study [Am J Med. 2014;127:95.e11-95.e17].
An adhesive electrocardiographic (ECG) monitoring patch detected significantly more arrhythmias compared with the conventionally used Holter monitor, according to results from a recent study [Am J Med. 2014;127:95.e11-95.e17].
An adhesive electrocardiographic...
02/19/2014
First Report Managed Care
Coprescribing Clarithromycin and a Calcium-Channel Blocker Increases Risk of Hospitalization in Older Patients
02/19/2014
Jill Sederstorm
Evidence shows that use of clarithromycin in older adults who are already taking calcium-channel blockers increases risk of hospitalization and acute kidney injury.
Evidence shows that use of clarithromycin in older adults who are already taking calcium-channel blockers increases risk of hospitalization and acute kidney injury.
Evidence shows that use of...
02/19/2014
First Report Managed Care
Patients Undergoing Bariatric Surgery Still Show Significant Weight Loss After 3 Years
02/19/2014
Jill Sederstorm
Severely obese patients who undergo bariatric surgery still have substantial weight loss 3 years after surgery, according to findings from a recent observational cohort study. Results from the second-phase of The Longitudinal Assessment of...
Severely obese patients who undergo bariatric surgery still have substantial weight loss 3 years after surgery, according to findings from a recent observational cohort study. Results from the second-phase of The Longitudinal Assessment of...
Severely obese patients who...
02/19/2014
First Report Managed Care
Medicare Managed Care Programs for Nursing Home Residents with Dementia
02/19/2014
A recent study combined data from a prospective cohort study with Medicare claims files to compare patterns of care and quality outcomes between nursing home residents with advanced dementia covered by managed care and individuals covered by...
A recent study combined data from a prospective cohort study with Medicare claims files to compare patterns of care and quality outcomes between nursing home residents with advanced dementia covered by managed care and individuals covered by...
A recent study combined data...
02/19/2014
First Report Managed Care
Examining Formulary Design and Provider Collaboration - Q & A with Jeffrey Dunn, PharmD, Senior Vice President of VRx Pharmacy Services
02/19/2014
First Report Managed Care conducted an interview with Jeffrey Dunn, PharmD, one of our Editorial Advisory Board members, to discuss his daily dealings with formulary management and opinion on changes under the Patient Protection and...
First Report Managed Care conducted an interview with Jeffrey Dunn, PharmD, one of our Editorial Advisory Board members, to discuss his daily dealings with formulary management and opinion on changes under the Patient Protection and...
First Report Managed Care...
02/19/2014
First Report Managed Care
Report Examines Medical Debt among Insured Individuals
02/19/2014
Eileen Koutnik-Fotopoulos
As many as 1 in 3 Americans report having difficulty paying their medical bills—defined as individuals having trouble affording medical bills within the past year, or they are gradually paying past bills over time, or they have bills they...
As many as 1 in 3 Americans report having difficulty paying their medical bills—defined as individuals having trouble affording medical bills within the past year, or they are gradually paying past bills over time, or they have bills they...
As many as 1 in 3 Americans...
02/19/2014
First Report Managed Care
Review of FDA Drug Approvals between 2005 and 2012
02/19/2014
Tim Casey
Nicholas Downing is a leading authority on an agency that decides the medications patients receive and the successes and failures of pharmaceutical companies.
Nicholas Downing is a leading authority on an agency that decides the medications patients receive and the successes and failures of pharmaceutical companies.
Nicholas Downing is a leading...
02/19/2014
First Report Managed Care
Prescription Drug Monitoring Programs to Curb Controlled Substance Abuse
02/19/2014
Tim Casey
Soon after actor Heath Ledger died from a prescription drug overdose in January 2008, Marc Fleming, PhD, was watching an entertainment news show. A guest mentioned that Mr. Ledger may have still been alive if providers had paid better...
Soon after actor Heath Ledger died from a prescription drug overdose in January 2008, Marc Fleming, PhD, was watching an entertainment news show. A guest mentioned that Mr. Ledger may have still been alive if providers had paid better...
Soon after actor Heath Ledger...
02/19/2014
First Report Managed Care

Behind the Bill

Behind the Bill
The Senate’s $3 Trillion Deal. Tax Relief Now, Medicaid Coverage Loss Later?
07/02/2025
Katie Hayes, MJ
The Senate has done it. After weeks of behind-the-scenes wrangling and last-minute amendments, lawmakers have passed a sprawling tax-and-spending megabill that makes good on a long-standing Republican goal: making the 2017 Trump tax cuts...
The Senate has done it. After weeks of behind-the-scenes wrangling and last-minute amendments, lawmakers have passed a sprawling tax-and-spending megabill that makes good on a long-standing Republican goal: making the 2017 Trump tax cuts...
The Senate has done it. After...
07/02/2025
First Report Managed Care
Behind the Bill
When a Cap Isn’t Just a Cap: How a Provider Tax Proposal Could Reshape Medicaid Financing
06/25/2025
Katie Hayes, MJ
In Washington, the most consequential policies are often buried in the fine print. One such detail in the Senate Finance Committee’s latest tax and spending proposal would gradually cap provider taxes—a core funding tool states use to pull in...
In Washington, the most consequential policies are often buried in the fine print. One such detail in the Senate Finance Committee’s latest tax and spending proposal would gradually cap provider taxes—a core funding tool states use to pull in...
In Washington, the most...
06/25/2025
First Report Managed Care
Behind the Bill
Rewriting the Safety Net? Inside the Senate’s Changes to Medicaid and the ACA
06/18/2025
Katie Hayes, MJ
Over the past few weeks, I’ve been following the progress of the One Big Beautiful Bill Act (OBBBA), which started in the House with sweeping tax reforms and some eye-catching health care proposals. Now, the Senate has released its (highly...
Over the past few weeks, I’ve been following the progress of the One Big Beautiful Bill Act (OBBBA), which started in the House with sweeping tax reforms and some eye-catching health care proposals. Now, the Senate has released its (highly...
Over the past few weeks, I’ve...
06/18/2025
First Report Managed Care
Behind the Bill
How States Might Respond to the One Big Beautiful Bill Act
06/11/2025
Katie Hayes, MJ
With the One Big Beautiful Bill Act (OBBBA) still in the hands of the Senate, much of the national conversation has centered on what this legislation would do to federal coverage programs. But regardless of how the federal process unfolds,...
With the One Big Beautiful Bill Act (OBBBA) still in the hands of the Senate, much of the national conversation has centered on what this legislation would do to federal coverage programs. But regardless of how the federal process unfolds,...
With the One Big Beautiful Bill...
06/11/2025
First Report Managed Care
Behind the Bill
Is the Affordable Care Act on the Chopping Block? What the One Big Beautiful Bill Act Tells Us.
06/04/2025
Katie Hayes, MJ
It’s been weeks of headline-grabbing debate over Medicaid work requirements, and the “One Big Beautiful Bill Act” remains in the Senate as they deliberate over several health care provisions. While the Medicaid provisions sparked most of the...
It’s been weeks of headline-grabbing debate over Medicaid work requirements, and the “One Big Beautiful Bill Act” remains in the Senate as they deliberate over several health care provisions. While the Medicaid provisions sparked most of the...
It’s been weeks of...
06/04/2025
First Report Managed Care
Behind the Bill
From House to Senate: The Journey of Cutting Medicaid
05/28/2025
Katie Hayes, MJ
Last week, the House of Representatives narrowly passed the One Big Beautiful Bill Act (HR 1, 119th Congress) by a single vote, sending the sweeping tax and spending reconciliation package, backed by President Trump, to the Senate. With its...
Last week, the House of Representatives narrowly passed the One Big Beautiful Bill Act (HR 1, 119th Congress) by a single vote, sending the sweeping tax and spending reconciliation package, backed by President Trump, to the Senate. With its...
Last week, the House of...
05/28/2025
First Report Managed Care
Behind the Bill
Eligibility, Paperwork, and Penalties: The Not-So-Hidden Costs of Medicaid ‘Reform’
05/21/2025
Katie Hayes, MJ
It’s been another eventful week in health policy—a phrase that’s quickly becoming routine. This time, House Republicans advanced a sweeping budget reconciliation bill, designed to implement elements of the March budget resolution, with a...
It’s been another eventful week in health policy—a phrase that’s quickly becoming routine. This time, House Republicans advanced a sweeping budget reconciliation bill, designed to implement elements of the March budget resolution, with a...
It’s been another eventful week...
05/21/2025
First Report Managed Care
Behind the Bill
A Busy Week in Drug Pricing Policy: Aligning US Drug Prices With Global Standards?
05/14/2025
Katie Hayes, MJ
It’s been a busy few days for drug pricing policy. While I’d love to dig into the details of both President Trump’s latest executive order and the newest Republican bill that would cut Medicaid spending, we don’t have the time—and this isn’t...
It’s been a busy few days for drug pricing policy. While I’d love to dig into the details of both President Trump’s latest executive order and the newest Republican bill that would cut Medicaid spending, we don’t have the time—and this isn’t...
It’s been a busy few days for...
05/14/2025
First Report Managed Care
BEHIND THE BILL
When Agencies Lose Power: How 3 Seismic Shifts are Transforming Pharmaceutical Regulation
05/07/2025
Katie Hayes, MJ
In the span of just 9 months, the landscape of administrative law has undergone a transformation so profound that pharmaceutical executives, health care providers, and patients alike are struggling to navigate the new terrain. The Supreme...
In the span of just 9 months, the landscape of administrative law has undergone a transformation so profound that pharmaceutical executives, health care providers, and patients alike are struggling to navigate the new terrain. The Supreme...
In the span of just 9 months,...
05/07/2025
First Report Managed Care
Behind the Bill
The Medicare Paradox, Part 3: Strategic Trade Doesn’t Have to be a Zero-Sum Game
05/07/2025
Katie Hayes, MJ
Over the past 2 weeks, I’ve examined the growing friction between the Section 232 pharmaceutical tariff investigations and the Medicare drug pricing reforms authorized by the Inflation Reduction Act (IRA). These 2 policy agendas—industrial...
Over the past 2 weeks, I’ve examined the growing friction between the Section 232 pharmaceutical tariff investigations and the Medicare drug pricing reforms authorized by the Inflation Reduction Act (IRA). These 2 policy agendas—industrial...
Over the past 2 weeks, I’ve...
05/07/2025
First Report Managed Care

Trending Articles

News
Comparative Effectiveness for Bronchodilator Responsiveness Testing
02/09/2024
Emry Lloyd
A new study compares the efficacy of salbutamol administration via a nebulizer vs a metered-dose inhaler with a spacer for bronchodilator responsiveness testing.
A new study compares the efficacy of salbutamol administration via a nebulizer vs a metered-dose inhaler with a spacer for bronchodilator responsiveness testing.
A new study compares the...
02/09/2024
First Report Managed Care
News
Trial to Test CAR T-Cell Therapy for Refractory Progressive MS
03/18/2024
Jolynn Tumolo
An autologous, fully human CD19 chimeric antigen receptor (CAR) T-cell product candidate recently received clearance from the US Food and Drug Administration (FDA) as an investigational new drug for the treatment of patients with refractory...
An autologous, fully human CD19 chimeric antigen receptor (CAR) T-cell product candidate recently received clearance from the US Food and Drug Administration (FDA) as an investigational new drug for the treatment of patients with refractory...
An autologous, fully human CD19...
03/18/2024
First Report Managed Care
Conference Coverage
PBM Legislation: Navigating Congressional Delays and Encouraging Progress
04/17/2024
Hannah Musick
Explore the world of federal pharmacy benefit manager (PBM) legislation and its potential impact on stakeholders in this in-depth analysis presented by Ross Margulies, JD, MPH, Partner and Co-Chair Healthcare and Life Sciences Coverage &...
Explore the world of federal pharmacy benefit manager (PBM) legislation and its potential impact on stakeholders in this in-depth analysis presented by Ross Margulies, JD, MPH, Partner and Co-Chair Healthcare and Life Sciences Coverage &...
Explore the world of federal...
04/17/2024
First Report Managed Care
Conference Coverage
The Impact of Fatigue on Prospective Memory in Persons With MS
05/23/2024
Hannah Musick
High fatigue levels in persons with multiple sclerosis (MS) are significantly associated with subjective impairment in prospective memory, particularly in tasks such as forgetting the date and missing appointments.
High fatigue levels in persons with multiple sclerosis (MS) are significantly associated with subjective impairment in prospective memory, particularly in tasks such as forgetting the date and missing appointments.
High fatigue levels in persons...
05/23/2024
First Report Managed Care
Interview
Enhancing Patient Services: Payer and Provider Considerations
06/28/2024
Patient services emerged as a central topic at AXS24, with many stakeholders emphasizing the need for consistency and accessibility in patient support. They also highlighted the importance of addressing both financial and emotional support...
Patient services emerged as a central topic at AXS24, with many stakeholders emphasizing the need for consistency and accessibility in patient support. They also highlighted the importance of addressing both financial and emotional support...
Patient services emerged as a...
06/28/2024
First Report Managed Care

February 2014 Volume 11 Issue 2

View Issue Archive
Editorial Correspondence

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use